A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Latest Information Update: 13 Jun 2024
At a glance
- Drugs STRO 001 (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sutro Biopharma
- 10 Jun 2024 Status changed from active, no longer recruiting to completed.
- 30 Mar 2023 According to a Sutro Biopharma media release, company has completed the dose-escalation part of this study in patients with non-Hodgkins lymphoma (NHL) and multiple myeloma (MM), after reaching a maximum tolerated dose (MTD).
- 12 Dec 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Jan 2023.